Adherence Intervention for Breast Cancer

Not yet recruiting at 3 trial locations
TF
Overseen ByTemidayo Fadelu, MD
Age: 18+
Sex: Female
Trial Phase: Academic
Sponsor: Dana-Farber Cancer Institute
Must be taking: Adjuvant endocrine therapy
Stay on Your Current MedsYou can continue your current medications while participating
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)

What You Need to Know Before You Apply

What is the purpose of this trial?

This study aims to evaluate a multi-modal intervention designed to improve adherence to adjuvant endocrine therapy (AET) among patients with ER-positive breast cancer in Rwanda. The intervention includes educational, behavioral, and reminder components, and will be assessed for feasibility and impact on medication adherence.

Who Is on the Research Team?

TF

Temidayo Fadelu, MD

Principal Investigator

Dana-Farber Cancer Institute

Are You a Good Fit for This Trial?

Inclusion Criteria

I am 18 years old or older.
My breast cancer is confirmed to be ER-positive.
I started anti-estrogen therapy 6 to 36 months ago.
See 4 more

Exclusion Criteria

Unable to comprehend study languages (English or Kinyarwanda)
Prisoners
Pregnant women
See 3 more

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Intervention

Participants receive a multi-modal medication adherence support package, including an educational video, a symptom monitoring card, and weekly text message reminders

6 months

Follow-up

Participants are monitored for adherence and quality of life using questionnaires and assessments

6 months

What Are the Treatments Tested in This Trial?

Interventions

  • AET Pilot Intervention

How Is the Trial Designed?

2

Treatment groups

Experimental Treatment

Active Control

Group I: InterventionExperimental Treatment3 Interventions
Group II: ControlActive Control1 Intervention

Find a Clinic Near You

Who Is Running the Clinical Trial?

Dana-Farber Cancer Institute

Lead Sponsor

Trials
1,128
Recruited
382,000+